![](https://monteverdelaw.com/wp-content/uploads/case-logo/dice-therapeutics-inc.png)
DICE Therapeutics, Inc. (NASDAQ: DICE), relating to its proposed sale to Eli Lilly and Co. Under the terms of the agreement, DICE shareholders are expected to receive $48.00 in cash per share they own.
DICE Therapeutics, Inc. (NASDAQ: DICE), relating to its proposed sale to Eli Lilly and Co. Under the terms of the agreement, DICE shareholders are expected to receive $48.00 in cash per share they own.